EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
NCT ID: NCT00338247
Last Updated: 2016-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
2006-07-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
NCT00820222
Lapatinib in Combination With Vinorelbine
NCT01013740
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
NCT00367471
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
NCT00777101
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
NCT00327743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lapatinib + capecitabine
Experimental
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prior treatment with hormonal therapy is allowed.
* Must have advanced or metastatic breast cancer with progression (as assessed by modified RECIST) after prior therapy, which must include all of the following: prior treatment with an anthracycline, a taxane, and trastuzumab alone or in combination with other therapy. Trastuzumab must have been administered in the adjuvant, or locally advanced or metastatic setting.
* Must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive for ErbB2 gene amplification. The status of ErbB2 expression must be documented prior to study entry.
* Must be \>/= 18 years of age
* Life expectancy of \> 8 weeks
* Must have recovered from side effects of previous treatment
* Patients with CNS mets are eligible provided treatment with prohibited medications as listed in the protocol are not required
* Cardiac ejection fraction must be within the institutional range of normal as measured by ECHO. MUGA scans are allowed if ECHOs cannot be performed
* Able to swallow and retain oral medications
* Must have adequate hematologic, hepatic and renal function
Exclusion Criteria
* Malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or bowel, or ulcerative colitis
* Concurrent disease or condition that would make the patient inappropriate for study participation
* Unresolved or unstable toxicity from prior administration of another investigational drug and/or prior cancer treatment
* Uncontrolled infection
* Active cardiac disease defined as history of uncontrolled or symptomatic angina; history of arrhythmias requiring medication, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation; MI \< 6 months from study entry; uncontrolled or symptomatic CHF; ejection fraction below the institutional normal limit; any other cardiac condition that would make this protocol unreasonably hazardous for the patient
* Receiving concurrent chemotherapy (other than capecitabine), radiation therapy, immunotherapy, biologic therapy or hormonal therapy for cancer. Concurrent therapy with bisphosphonates is allowed
* History of allergic reaction attributed to compounds of similar composition to lapatinib or any excipients
* History of allergic reactions attributed to compounds of similar chemical composition to capecitabine, fluorouracil or excipients
* Known DPD deficiency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Huntsville, Alabama, United States
Novartis Investigative Site
Anchorage, Alaska, United States
Novartis Investigative Site
Glendale, Arizona, United States
Novartis Investigative Site
Fayetteville, Arkansas, United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Bellflower, California, United States
Novartis Investigative Site
Burbank, California, United States
Novartis Investigative Site
Gilroy, California, United States
Novartis Investigative Site
Long Beach, California, United States
Novartis Investigative Site
Long Beach, California, United States
Novartis Investigative Site
Newport Beach, California, United States
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Santa Rosa, California, United States
Novartis Investigative Site
Stockton, California, United States
Novartis Investigative Site
Aurora, Colorado, United States
Novartis Investigative Site
Boulder, Colorado, United States
Novartis Investigative Site
Lafayette, Colorado, United States
Novartis Investigative Site
Hartford, Connecticut, United States
Novartis Investigative Site
Manchester, Connecticut, United States
Novartis Investigative Site
New Havey, Connecticut, United States
Novartis Investigative Site
Norwich, Connecticut, United States
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Novartis Investigative Site
Fort Lauderdale, Florida, United States
Novartis Investigative Site
Fort Myers, Florida, United States
Novartis Investigative Site
Fort Walton Beach, Florida, United States
Novartis Investigative Site
Gainesville, Florida, United States
Novartis Investigative Site
Hollywood, Florida, United States
Novartis Investigative Site
Jacksonville, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Orlando, Florida, United States
Novartis Investigative Site
Orlando, Florida, United States
Novartis Investigative Site
Tampa, Florida, United States
Novartis Investigative Site
Augusta, Georgia, United States
Novartis Investigative Site
Brunswick, Georgia, United States
Novartis Investigative Site
Macon, Georgia, United States
Novartis Investigative Site
Marietta, Georgia, United States
Novartis Investigative Site
Tucker, Georgia, United States
Novartis Investigative Site
Honolulu, Hawaii, United States
Novartis Investigative Site
Boise, Idaho, United States
Novartis Investigative Site
Chicago, Illinois, United States
Novartis Investigative Site
Decatur, Illinois, United States
Novartis Investigative Site
Galesburg, Illinois, United States
Novartis Investigative Site
Highland Park, Illinois, United States
Novartis Investigative Site
Joliet, Illinois, United States
Novartis Investigative Site
Peoria, Illinois, United States
Novartis Investigative Site
Zion, Illinois, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Bettendorf, Iowa, United States
Novartis Investigative Site
Cedar Rapids, Iowa, United States
Novartis Investigative Site
Council Bluffs, Iowa, United States
Novartis Investigative Site
Sioux City, Iowa, United States
Novartis Investigative Site
Waterloo, Iowa, United States
Novartis Investigative Site
Baton Rouge, Louisiana, United States
Novartis Investigative Site
Metairie, Louisiana, United States
Novartis Investigative Site
Portland, Maine, United States
Novartis Investigative Site
Scarborough, Maine, United States
Novartis Investigative Site
Waterville, Maine, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Chevy Chase, Maryland, United States
Novartis Investigative Site
Frederick, Maryland, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Fall River, Massachusetts, United States
Novartis Investigative Site
Peabody, Massachusetts, United States
Novartis Investigative Site
Ann Arbor, Michigan, United States
Novartis Investigative Site
Detroit, Michigan, United States
Novartis Investigative Site
Royal Oak, Michigan, United States
Novartis Investigative Site
Troy, Michigan, United States
Novartis Investigative Site
Duluth, Minnesota, United States
Novartis Investigative Site
Jackson, Mississippi, United States
Novartis Investigative Site
Columbia, Missouri, United States
Novartis Investigative Site
Kalamazoo, Missouri, United States
Novartis Investigative Site
Kansas City, Missouri, United States
Novartis Investigative Site
Springfield, Missouri, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Billings, Montana, United States
Novartis Investigative Site
Great Falls, Montana, United States
Novartis Investigative Site
Grand Island, Nebraska, United States
Novartis Investigative Site
Lincoln, Nebraska, United States
Novartis Investigative Site
North Platte, Nebraska, United States
Novartis Investigative Site
Omaha, Nebraska, United States
Novartis Investigative Site
Omaha, Nebraska, United States
Novartis Investigative Site
Las Vegas, Nevada, United States
Novartis Investigative Site
Exeter, New Hampshire, United States
Novartis Investigative Site
Flemington, New Jersey, United States
Novartis Investigative Site
Freehold, New Jersey, United States
Novartis Investigative Site
Little Silver, New Jersey, United States
Novartis Investigative Site
Livingston, New Jersey, United States
Novartis Investigative Site
Mountain Lakes, New Jersey, United States
Novartis Investigative Site
Newark, New Jersey, United States
Novartis Investigative Site
Buffalo, New York, United States
Novartis Investigative Site
Buffalo, New York, United States
Novartis Investigative Site
East Setauket, New York, United States
Novartis Investigative Site
East Syracuse, New York, United States
Novartis Investigative Site
Fresh Meadows, New York, United States
Novartis Investigative Site
Glens Falls, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
Asheville, North Carolina, United States
Novartis Investigative Site
Charlotte, North Carolina, United States
Novartis Investigative Site
Charlotte, North Carolina, United States
Novartis Investigative Site
Fayetteville, North Carolina, United States
Novartis Investigative Site
Greensboro, North Carolina, United States
Novartis Investigative Site
Bismarck, North Dakota, United States
Novartis Investigative Site
Fargo, North Dakota, United States
Novartis Investigative Site
Cincinnati, Ohio, United States
Novartis Investigative Site
Cincinnati, Ohio, United States
Novartis Investigative Site
Cleveland, Ohio, United States
Novartis Investigative Site
Columbus, Ohio, United States
Novartis Investigative Site
Columbus, Ohio, United States
Novartis Investigative Site
Sandusky, Ohio, United States
Novartis Investigative Site
Oklahoma City, Oklahoma, United States
Novartis Investigative Site
Tulsa, Oklahoma, United States
Novartis Investigative Site
Tulsa, Oklahoma, United States
Novartis Investigative Site
Klamath Falls, Oregon, United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Drexel Hill, Pennsylvania, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States
Novartis Investigative Site
Pottstown, Pennsylvania, United States
Novartis Investigative Site
Sayre, Pennsylvania, United States
Novartis Investigative Site
State College, Pennsylvania, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Columbia, South Carolina, United States
Novartis Investigative Site
Florence, South Carolina, United States
Novartis Investigative Site
Mt. Pleasant, South Carolina, United States
Novartis Investigative Site
Knoxville, Tennessee, United States
Novartis Investigative Site
Memphis, Tennessee, United States
Novartis Investigative Site
Nashville, Tennessee, United States
Novartis Investigative Site
Arlington, Texas, United States
Novartis Investigative Site
Austin, Texas, United States
Novartis Investigative Site
Austin, Texas, United States
Novartis Investigative Site
Dallas, Texas, United States
Novartis Investigative Site
Dallas, Texas, United States
Novartis Investigative Site
El Paso, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
San Antonio, Texas, United States
Novartis Investigative Site
Salt Lake City, Utah, United States
Novartis Investigative Site
Fairfax, Virginia, United States
Novartis Investigative Site
Richmond, Virginia, United States
Novartis Investigative Site
Richmond, Virginia, United States
Novartis Investigative Site
Kennewick, Washington, United States
Novartis Investigative Site
Mount Vernon, Washington, United States
Novartis Investigative Site
Seattle, Washington, United States
Novartis Investigative Site
Tacoma, Washington, United States
Novartis Investigative Site
Walla Walla, Washington, United States
Novartis Investigative Site
Morgantown, West Virginia, United States
Novartis Investigative Site
Green Bay, Wisconsin, United States
Novartis Investigative Site
La Crosse, Wisconsin, United States
Novartis Investigative Site
Marshfield, Wisconsin, United States
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Port Macquarie, New South Wales, Australia
Novartis Investigative Site
Waratah, New South Wales, Australia
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
South Brisbane, Queensland, Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Hobart, Tasmania, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Fitzroy, Victoria, Australia
Novartis Investigative Site
Geelong, Victoria, Australia
Novartis Investigative Site
Wodonga, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Perth, Western Australia, Australia
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Innsbruck, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Salzburg, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Charleroi, , Belgium
Novartis Investigative Site
Edegem, , Belgium
Novartis Investigative Site
Ghent, , Belgium
Novartis Investigative Site
Haine-Saint-Paul, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Liège, , Belgium
Novartis Investigative Site
Wilrijk, , Belgium
Novartis Investigative Site
Yvoir, , Belgium
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Jaú, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Sofia, , Bulgaria
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Winnipeg, Manitoba, Canada
Novartis Investigative Site
Moncton, New Brunswick, Canada
Novartis Investigative Site
Greater Sudbury, Ontario, Canada
Novartis Investigative Site
Oshawa, Ontario, Canada
Novartis Investigative Site
Greenfield Park, Quebec, Canada
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada
Novartis Investigative Site
Santiago, Región Metro de Santiago, Chile
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Dalian, Liaoning, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Beijing, , China
Novartis Investigative Site
Beijing, , China
Novartis Investigative Site
Shanghai, , China
Novartis Investigative Site
Shanghai, , China
Novartis Investigative Site
Tianjin, , China
Novartis Investigative Site
Stróvolos, , Cyprus
Novartis Investigative Site
Brno, , Czechia
Novartis Investigative Site
Olomouc, , Czechia
Novartis Investigative Site
Prague, , Czechia
Novartis Investigative Site
Prague, , Czechia
Novartis Investigative Site
Århus C, , Denmark
Novartis Investigative Site
Copenhagen, , Denmark
Novartis Investigative Site
Odense C, , Denmark
Novartis Investigative Site
Roskilde, , Denmark
Novartis Investigative Site
Vejle, , Denmark
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tartu, , Estonia
Novartis Investigative Site
Hämeenlinna, , Finland
Novartis Investigative Site
Helsinki, , Finland
Novartis Investigative Site
Kangasala, , Finland
Novartis Investigative Site
Kuopio, , Finland
Novartis Investigative Site
OYS, , Finland
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Stuttgart, Baden-Wurttemberg, Germany
Novartis Investigative Site
Tübingen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Augsburg, Bavaria, Germany
Novartis Investigative Site
Hamburg, City state of Hamburg, Germany
Novartis Investigative Site
Marburg, Hesse, Germany
Novartis Investigative Site
Wiesbaden, Hesse, Germany
Novartis Investigative Site
Braunschweig, Lower Saxony, Germany
Novartis Investigative Site
Hanover, Lower Saxony, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Ibbenbueren, North Rhine-Westphalia, Germany
Novartis Investigative Site
Mönchengladbach, North Rhine-Westphalia, Germany
Novartis Investigative Site
Troisdorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Mainz, Rhineland-Palatinate, Germany
Novartis Investigative Site
Saarbrücken, Saarland, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Novartis Investigative Site
Magdeburg, Saxony-Anhalt, Germany
Novartis Investigative Site
Lübeck, Schleswig-Holstein, Germany
Novartis Investigative Site
Berlin, State of Berlin, Germany
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Heraklion, Crete, , Greece
Novartis Investigative Site
Marousi, , Greece
Novartis Investigative Site
Pokfulam, , Hong Kong
Novartis Investigative Site
Shatin, , Hong Kong
Novartis Investigative Site
Reykjavik, , Iceland
Novartis Investigative Site
Jakarta, , Indonesia
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Galway, , Ireland
Novartis Investigative Site
Tallaght, Dublin, , Ireland
Novartis Investigative Site
Wilton, Cork, , Ireland
Novartis Investigative Site
Beersheba, , Israel
Novartis Investigative Site
Haifa, , Israel
Novartis Investigative Site
Jerusalem, , Israel
Novartis Investigative Site
Petah Tikva, , Israel
Novartis Investigative Site
Ramat Gan, , Israel
Novartis Investigative Site
Rehovot, , Israel
Novartis Investigative Site
Tel Aviv, , Israel
Novartis Investigative Site
Bari, Apulia, Italy
Novartis Investigative Site
San Giovanni Rotondo (FG), Apulia, Italy
Novartis Investigative Site
Potenza, Basilicate, Italy
Novartis Investigative Site
Reggio Calabria, Calabria, Italy
Novartis Investigative Site
Napoli, Campania, Italy
Novartis Investigative Site
Forlì, Emilia-Romagna, Italy
Novartis Investigative Site
Modena, Emilia-Romagna, Italy
Novartis Investigative Site
Aviano (PN), Friuli Venezia Giulia, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Genoa, Liguria, Italy
Novartis Investigative Site
Bergamo, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Candiolo (TO), Piedmont, Italy
Novartis Investigative Site
Turin, Piedmont, Italy
Novartis Investigative Site
Palermo, Sicily, Italy
Novartis Investigative Site
Bolzano, Trentino-Alto Adige, Italy
Novartis Investigative Site
Florence, Tuscany, Italy
Novartis Investigative Site
Pisa, Tuscany, Italy
Novartis Investigative Site
Perugia, Umbria, Italy
Novartis Investigative Site
Ancona, , Italy
Novartis Investigative Site
Cagliari, , Italy
Novartis Investigative Site
Chieti, , Italy
Novartis Investigative Site
Macerata, , Italy
Novartis Investigative Site
Padua, , Italy
Novartis Investigative Site
Trieste, , Italy
Novartis Investigative Site
Luxembourg, , Luxembourg
Novartis Investigative Site
Kuala Lumpur, , Malaysia
Novartis Investigative Site
Kuala Lumpur, , Malaysia
Novartis Investigative Site
Petaling Jaya Selangor, , Malaysia
Novartis Investigative Site
Floriana, , Malta
Novartis Investigative Site
Tijuana, Baja California Norte, Mexico
Novartis Investigative Site
Toluca, Edo Mex, State of Mexico, Mexico
Novartis Investigative Site
Mérida, Yucatán, Mexico
Novartis Investigative Site
Durango, , Mexico
Novartis Investigative Site
Mexico City, , Mexico
Novartis Investigative Site
Amersfoort, , Netherlands
Novartis Investigative Site
Amsterdam, , Netherlands
Novartis Investigative Site
Amsterdam, , Netherlands
Novartis Investigative Site
Dordrecht, , Netherlands
Novartis Investigative Site
Enschede, , Netherlands
Novartis Investigative Site
Groningen, , Netherlands
Novartis Investigative Site
Leeuwarden, , Netherlands
Novartis Investigative Site
Leiden, , Netherlands
Novartis Investigative Site
Maastricht, , Netherlands
Novartis Investigative Site
Christchurch, , New Zealand
Novartis Investigative Site
Dunedin, , New Zealand
Novartis Investigative Site
Newtown, Wellington, , New Zealand
Novartis Investigative Site
Lima, Lima Province, Peru
Novartis Investigative Site
Lima, Lima Province, Peru
Novartis Investigative Site
Makati City, , Philippines
Novartis Investigative Site
Pasay, , Philippines
Novartis Investigative Site
Quezon City, , Philippines
Novartis Investigative Site
Sampaloc Manila, , Philippines
Novartis Investigative Site
Bialystok, , Poland
Novartis Investigative Site
Bydgoszcz, , Poland
Novartis Investigative Site
Elblag, , Poland
Novartis Investigative Site
Gdansk, , Poland
Novartis Investigative Site
Gliwice, , Poland
Novartis Investigative Site
Olsztyn, , Poland
Novartis Investigative Site
Olsztyn, , Poland
Novartis Investigative Site
Poznan, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Evora, , Portugal
Novartis Investigative Site
Lisbon, , Portugal
Novartis Investigative Site
Lisbon, , Portugal
Novartis Investigative Site
Porto, , Portugal
Novartis Investigative Site
Porto, , Portugal
Novartis Investigative Site
Bucharest, , Romania
Novartis Investigative Site
Iași, , Romania
Novartis Investigative Site
Sibiu, , Romania
Novartis Investigative Site
Timișoara, , Romania
Novartis Investigative Site
Irkutsk, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Nizhny Novgorod, , Russia
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Banská Bystrica, , Slovakia
Novartis Investigative Site
Bratislava, , Slovakia
Novartis Investigative Site
Bratislava, , Slovakia
Novartis Investigative Site
Košice, , Slovakia
Novartis Investigative Site
Poprad, , Slovakia
Novartis Investigative Site
Ljubljana, , Slovenia
Novartis Investigative Site
Maribor, , Slovenia
Novartis Investigative Site
Kyunggi-do, , South Korea
Novartis Investigative Site
Pusan, , South Korea
Novartis Investigative Site
Seodaemun-gu, Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Songpa-gu, Seoul, , South Korea
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Basurto/Bilbao, , Spain
Novartis Investigative Site
Burgos, , Spain
Novartis Investigative Site
Cáceres, , Spain
Novartis Investigative Site
Elche, , Spain
Novartis Investigative Site
Girona, , Spain
Novartis Investigative Site
Jaén, , Spain
Novartis Investigative Site
Lleida, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Málaga, , Spain
Novartis Investigative Site
Murcia, , Spain
Novartis Investigative Site
Palencia, , Spain
Novartis Investigative Site
Palma de Mallorca, , Spain
Novartis Investigative Site
Pamplona, , Spain
Novartis Investigative Site
Pontevedra, , Spain
Novartis Investigative Site
San Sebastián, , Spain
Novartis Investigative Site
Santa Cruz de Tenerife, , Spain
Novartis Investigative Site
Santiago, , Spain
Novartis Investigative Site
Toledo, , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative Site
Zaragoza, , Spain
Novartis Investigative Site
Jönköping, , Sweden
Novartis Investigative Site
Lund, , Sweden
Novartis Investigative Site
Stockholm, , Sweden
Novartis Investigative Site
Umeå, , Sweden
Novartis Investigative Site
Uppsala, , Sweden
Novartis Investigative Site
Basel, , Switzerland
Novartis Investigative Site
Bern, , Switzerland
Novartis Investigative Site
Chur, , Switzerland
Novartis Investigative Site
Geneva, , Switzerland
Novartis Investigative Site
Mendrisio, , Switzerland
Novartis Investigative Site
Neuchâtel, , Switzerland
Novartis Investigative Site
Sankt Gallen, , Switzerland
Novartis Investigative Site
Zurich, , Switzerland
Novartis Investigative Site
Kaohsiung City, , Taiwan
Novartis Investigative Site
Taichung, , Taiwan
Novartis Investigative Site
Tainan City, , Taiwan
Novartis Investigative Site
Tainan County, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Chiang Mai, , Thailand
Novartis Investigative Site
Pathum Thani, , Thailand
Novartis Investigative Site
Chernivtsi, , Ukraine
Novartis Investigative Site
Kiev, , Ukraine
Novartis Investigative Site
Odesa, , Ukraine
Novartis Investigative Site
Rivne, , Ukraine
Novartis Investigative Site
Cambridge, Cambridgeshire, United Kingdom
Novartis Investigative Site
Chelmsford, Essex, United Kingdom
Novartis Investigative Site
Northwood, Middlesex, United Kingdom
Novartis Investigative Site
Edinburgh, Midlothian, United Kingdom
Novartis Investigative Site
Belfast, , United Kingdom
Novartis Investigative Site
Bournemouth, , United Kingdom
Novartis Investigative Site
Brighton, , United Kingdom
Novartis Investigative Site
Bristol, , United Kingdom
Novartis Investigative Site
Cardiff, , United Kingdom
Novartis Investigative Site
Cheltenham, , United Kingdom
Novartis Investigative Site
Colchester, , United Kingdom
Novartis Investigative Site
Cumbria, , United Kingdom
Novartis Investigative Site
Denbighshire, , United Kingdom
Novartis Investigative Site
Hartshill, Stoke-on-Trent, , United Kingdom
Novartis Investigative Site
Lindley, Huddersfield, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
Manchester, , United Kingdom
Novartis Investigative Site
Nottingham, , United Kingdom
Novartis Investigative Site
Peterborough, , United Kingdom
Novartis Investigative Site
Poole, Dorset, , United Kingdom
Novartis Investigative Site
Portsmouth, , United Kingdom
Novartis Investigative Site
Shrewsbury, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ro J, Park S, Kim S, Kim TY, Im YH, Rha SY, Chung JS, Moon H, Santillana S. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer. 2012 Jul 28;12:322. doi: 10.1186/1471-2407-12-322.
Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EGF103659
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.